Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | DGKA | P23743 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24925214 | 0.98 | THRB (0.52) | THRBALDH1A1TSHRMGAMGAA | |
| SCHEMBL14601342 | 0.84 | HSD17B10 (0.43) | THRBALDH1A1TSHRMGAMGAA | |
| SCHEMBL1070358 | 0.84 | THRB (0.61) | THRBALDH1A1TSHRMGAMGAA | |
| SCHEMBL5943658 | 0.84 | MEN1 (0.41) | THRBALDH1A1TSHREPHX2HSD17B10 | |
| SCHEMBL24925001 | 0.82 | THRB (0.55) | THRBALDH1A1TSHRMGAMGAA | |
| SCHEMBL528571 | 0.81 | HCAR2 (0.39) | ALDH1A1TSHRMGAMGAASI | |
| Methacrylic Acid SCHEMBL27748603 | 0.81 | THRB (0.58) | THRBALDH1A1TSHRMGAMGAA | |
| SCHEMBL262251 | 0.81 | GAA (0.61) | ALDH1A1TSHRMGAMGAASI | |
| SCHEMBL9598368 | 0.80 | ALDH1A1 (0.62) | THRBALDH1A1TSHRMGAMGAA | |
| SCHEMBL6518056 | 0.79 | ALDH1A1 (0.52) | THRBALDH1A1TSHRMGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3962888-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | Sitryx Therapeutics Limited (GB) | 2022-03-09 | — | — | EP | claimed |
| CN-113825740-A | Itaconic acid derivatives and their use in the treatment of inflammatory diseases or diseases associated with adverse immune reactions | 西特瑞治疗有限公司 | 2021-12-21 | — | — | CN | claimed |
| WO-2020222011-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LIMITED (GB) | 2020-11-05 | — | — | WO | claimed |
| US-12390437-B2 | Itaconic acid derivatives and uses thereof intreating an inflammatory disease or a disease associated with an undesirable immune response | SITRYX THERAPEUTICS LIMITED (GB) | 2025-08-19 | — | — | US | disclosed |
| US-20220265595-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF INTREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LIMITED (GB) | 2022-08-25 | — | — | US | disclosed |
| EP-3962888-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | Sitryx Therapeutics Limited (GB) | 2022-03-09 | — | — | EP | disclosed |
| CN-113825740-A | Itaconic acid derivatives and their use in the treatment of inflammatory diseases or diseases associated with adverse immune reactions | 西特瑞治疗有限公司 | 2021-12-21 | — | — | CN | disclosed |
| WO-2020222011-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LIMITED (GB) | 2020-11-05 | — | — | WO | disclosed |
| WO-2020222011-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LIMITED (GB) | 2020-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265595-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF INTREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | IL1R1, IL1B, IL1A | THRB 4241/4885ALDH1A1 9/4885TSHR 3856/4885 |
| US-12390437-B2 | Itaconic acid derivatives and uses thereof intreating an inflammatory disease or a disease associated with an undesirable immune response | IL1R1, IL1B, IL1A | THRB 4241/4885ALDH1A1 9/4885TSHR 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.